Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HLX79 plus rituximab versus placebo in active glomerulonephritis
CTR20251999Phase 2Active
- Sponsor
- HyBioPharma
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Glomerulonephritis (GN), membranous glomerulonephritis (MGN) and lupus nephritis (LN) comparing HLX79 + rituximab with Placebo control (2 arms). Started Jul 2025; status: active.
02
Drugs
efgitasialase alfarituximab
03
Conditions
Glomerulonephritis (GN)membranous glomerulonephritis (MGN)lupus nephritis (LN)
Beyond the preview
Go deeper on CTR20251999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251999.